Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
Opt-in decision is based on interim results from the pivotal COSMIC-311 Phase III trial in people living with radioiodine-refractory differentiated thyroid cancer 1 Detailed results will be presented at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meet...
Ipsen S.A. (IPSEY): Q1 Revenue of €658.5M (+0.6% Y/Y)."Ipsen’s Oncology medicines stood out in the period, while the regulatory approval in Europe of the Cabometyx® combination with nivolumab in first-line renal cell carcinoma marked the start of an important launch. T...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, publishes its sales performance for the first quarter of 2021: Q1 2021 sales summary (unaudited IFRS consolidated sales) Highlights Total Sales growth o...
Fusion Pharmaceuticals (FUSN) has completed the acquisition of IPN-1087, a small molecule targeting tumors, from Ipsen (IPSEY).Fusion intends to use IPN-1087, which targets the protein neurotensin receptor 1 (NTSR1), to create an alpha-emitting radiopharmaceutical, FPI-2059, for sol...
Fusion Pharmaceuticals Announces Closing of Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen PR Newswire HAMILTON , ON and BOSTON , April 1, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncol...
Exelixis ([[EXEL]] +3.7%) announced that its partner Ipsen ([[IPSEY]] +3.9%) has secured the European Commission approval for Cabometyx (cabozantinib)/ Opdivo (nivolumab) combination as a first-line treatment in advanced renal cell carcinoma.Cabometyx and Opdivo will now be commerci...
Approval based on pivotal Phase III CheckMate-9ER trial data, also recently published in the New England Journal of Medicine 1 Trial data showed Cabometyx ® (cabozantinib) in combination with Opdivo ® (nivolumab) doubled medianprogression-free survival an...
Fusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen PR Newswire Fusion to Leverage its Targeted Alpha Therapies (TAT) Expertise to Create FPI-2059, an Alpha-Emitting Radiopharmaceutical Targeting Solid Tu...
Recommendation based on the Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in combination with Opdivo® (nivolumab) doubled progression-free survival and significantly improved overall survival and response rates 1 Cabometyx® in combination wi...
A total of 9 abstracts presented at the 18th Annual European Neuroendocrine Tumor Society (ENETS) Conference showcasing new data across the patient pathway in neuroendocrine tumors Latest data from the Phase II CLARINET FORTE study are the subject of an oral presentation showing q...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...